Current Progress of CAR-T Cell Therapy in Lung Cancer
DOI:
https://doi.org/10.54097/2t70f520Keywords:
lung cancer; CAR-T therapy; progress of treatment.Abstract
Lung cancer is one of the most common malignancies in the world. For lung cancer treatment, traditional surgery, radiotherapy, chemotherapy, monoclonal antibody therapy and other therapeutic methods can have a certain therapeutic effect, but the prognosis of these treatment methods is generally poor. The recurrence rate of patients treated with surgery is high, and chemoradiotherapy may cause damage to normal cells and tissues with serious side effects. Drug resistance is also a very serious side effect when using monoclonal antibody drugs. So, a better treatment is needed. CAR-T has been investigated in the past as a potential treatment for lung cancer. CAR-T for lung cancer is now undergoing clinical testing. Finding viable therapeutic targets is essential for CAR-T therapy for lung cancer, and there are numerous antigenic targets for this type of treatment. The advancement of CAR-T therapy, its relevant targets for lung cancer treatment, and the shortcomings of traditional methods will be discussed in this review.
Downloads
References
Lahiri, A., Maji, A., Potdar, P. D., Singh, N., Parikh, P., Bisht, B., Mukherjee, A., & Paul, M. K. Lung cancer immunotherapy: Progress, pitfalls, and promises. Molecular Cancer,2023,22,40.
Mao, X., Xu, J., Wang, W., Liang, C., Hua, J., Liu, J., Zhang, B., Meng, Q., Yu, X., & Shi, S. Crosstalk between cancer-associated fibroblasts and immune cells in the tumor microenvironment: New findings and future perspectives. Molecular Cancer, 2021,20, 131.
Jaspers, J. E., Khan, J. F., Godfrey, W. D., Lopez, A. V., Ciampricotti, M., Rudin, C. M., & Brentjens, R. J. (n.d.). IL-18–secreting CAR T cells targeting DLL3 are highly effective in small cell lung cancer models. The Journal of Clinical Investigation,2023, 133(9), e166028.
Xiao, B.-F., Zhang, J.-T., Zhu, Y.-G., Cui, X.-R., Lu, Z.-M., Yu, B.-T., & Wu, N. Chimeric Antigen Receptor T-Cell Therapy in Lung Cancer : Potential and Challenges. Frontiers in Immunology, 2021,12, 782775.
Chang Chunyu. Research progress of radiation-induced cardiac injury in non-small cell lung cancer [J]. Laboratory Medicine and Clinic,2023,20(5):712-716.
Li Na, Li Dan, Xie Hui, et al. Construction of clinical prediction model of radiation pneumonia in patients with lung cancer treated with intensity modulated radiation therapy [J]. Chinese medical equipment,2023,20(6):23-28.
Hauner, K., Maisch, P., & Retz, M. Nebenwirkungen der Chemotherapie [Side effects of chemotherapy]. Der Urologe. Ausg. A, 2017,56(4), 472–479.
Lyman, G. H., Abella, E., & Pettengell, R. Risk factors for febrile neutropenia among patients with cancer receiving chemotherapy: A systematic review. Critical Reviews in Oncology/Hematology, 2014,90(3), 190–199.
Dabas, P., & Danda, A. Revolutionizing cancer treatment: A comprehensive review of CAR-T cell therapy. Medical Oncology, 2023,40(9), 275.
Utkarsh, K., Srivastava, N., Kumar, S., Khan, A., Dagar, G., Kumar, M., Singh, M., & Haque, S. CAR-T cell therapy : a game-changer in cancer treatment and beyond. Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2024, 10.1007/s12094-023-03368-2. Advance online publication.
Mitra, A., Barua, A., Huang, L., Ganguly, S., Feng, Q., & He, B. From bench to bedside: The history and progress of CAR T cell therapy. Frontiers in Immunology, 2023,14, 1188049.
Liu, H., Ma, Y., Yang, C., Xia, S., Pan, Q., Zhao, H., Fang, W., Chen, X., Zhang, Y., Zou, B., Li, Q., Wan, Y., Chen, H., Tang, Y., Zhao, J., Weng, D., Xia, L., Zhang, L., & Xia, J. Severe delayed pulmonary toxicity following PD‐L1–specific CAR‐T cell therapy for non‐small cell lung cancer. Clinical & Translational Immunology, 2020, 9(10), e1154.
Li, H., Huang, Y., Jiang, DQ. et al. Antitumor activity of EGFR-specific CAR T cells against non-small-cell lung cancer cells in vitro and in mice. Cell Death Dis,2018, 9, 177.
Feng, K., Guo, Y., Dai, H., Wang, Y., Li, X., Jia, H., & Han, W. Chimeric antigen receptor-modified T cells for the immunotherapy of patients with EGFR-expressing advanced relapsed/refractory non-small cell lung cancer. Science China. Life sciences, 2016,59(5), 468–479.
Morello, A., Sadelain, M., & Adusumilli, P. S. Mesothelin-Targeted CARs: Driving T cells to Solid Tumors. Cancer Discovery, 2016,6(2), 133–146.
Ye, L., Lou, Y., Lu, L., & Fan, X. Mesothelin-targeted second generation CAR-T cells inhibit growth of mesothelin-expressing tumors in vivo. Experimental and Therapeutic Medicine, 2019, 17(1), 739–747.
Yong, C. S. M., Dardalhon, V., Devaud, C., Taylor, N., Darcy, P. K., & Kershaw, M. H. CAR T-cell therapy of solid tumors. Immunology and Cell Biology, 2017, 95(4), 356–363.
Brog, R. A., Ferry, S. L., Schiebout, C. T., Messier, C. M., Cook, W. J., Abdullah, L., Zou, J., Kumar, P., Sentman, C. L., Frost, H. R., & Huang, Y. H. Superkine IL-2 and IL-33 Armored CAR T Cells Reshape the Tumor Microenvironment and Reduce Growth of Multiple Solid Tumors. Cancer immunology research, 2022, 10(8), 962–977.
Whilding, L. M., Halim, L., Draper, B., Parente-Pereira, A. C., Zabinski, T., Davies, D. M., & Maher, J. CAR T-Cells Targeting the Integrin αvβ6 and Co-Expressing the Chemokine Receptor CXCR2 Demonstrate Enhanced Homing and Efficacy against Several Solid Malignancies. Cancers, 2019, 11(5), 674.
Kotch, C., Barrett, D., & Teachey, D. T. Tocilizumab for the treatment of chimeric antigen receptor T cell-induced cytokine release syndrome. Expert review of clinical immunology, 2019, 15(8), 813–822.
Downloads
Published
Issue
Section
License
Copyright (c) 2024 Highlights in Science, Engineering and Technology
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
